{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:48:40Z","timestamp":1790635720880,"version":"4.1.0"},"reference-count":23,"publisher":"American Society of Hematology","issue":"26","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The primary cause of morbidity and mortality in patients with multiple myeloma (MM) is an infection. Therefore, there is great concern about susceptibility to the outcome of COVID-19\u2013infected patients with MM. This retrospective study describes the baseline characteristics and outcome data of COVID-19 infection in 650 patients with plasma cell disorders, collected by the International Myeloma Society to understand the initial challenges faced by myeloma patients during the COVID-19 pandemic. Analyses were performed for hospitalized MM patients. Among hospitalized patients, the median age was 69 years, and nearly all patients (96%) had MM. Approximately 36% were recently diagnosed (2019-2020), and 54% of patients were receiving first-line therapy. Thirty-three percent of patients have died, with significant geographic variability, ranging from 27% to 57% of hospitalized patients. Univariate analysis identified age, International Staging System stage 3 (ISS3), high-risk disease, renal disease, suboptimal myeloma control (active or progressive disease), and 1 or more comorbidities as risk factors for higher rates of death. Neither history of transplant, including within a year of COVID-19 diagnosis, nor other anti-MM treatments were associated with outcomes. Multivariate analysis found that only age, high-risk MM, renal disease, and suboptimal MM control remained independent predictors of adverse outcome with COVID-19 infection. The management of MM in the era of COVID-19 requires careful consideration of patient- and disease-related factors to decrease the risk of acquiring COVID-19 infection, while not compromising disease control through appropriate MM treatment. This study provides initial data to develop recommendations for the management of MM patients with COVID-19 infection.<\/jats:p>","DOI":"10.1182\/blood.2020008150","type":"journal-article","created":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T14:39:31Z","timestamp":1604673571000},"page":"3033-3040","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":170,"title":["Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set"],"prefix":"10.1182","volume":"136","author":[{"given":"Ajai","family":"Chari","sequence":"first","affiliation":[{"name":"Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Kemal","family":"Samur","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA;"},{"name":"Department of Data Science, Harvard T. H. Chan School of Public Health, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7908-0063","authenticated-orcid":false,"given":"Joaquin","family":"Martinez-Lopez","sequence":"additional","affiliation":[{"name":"Instituto de Investigaci\u00f3n, Hospital Universitario 12 de Octubre (i+12), Madrid, Spain;"},{"name":"Centro Nacional de Investigaciones Oncol\u00f3gicas (CNIO), Complutense University, Madrid, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1717-0412","authenticated-orcid":false,"given":"Gordon","family":"Cook","sequence":"additional","affiliation":[{"name":"Leeds Institute of Clinical Trial Research and"},{"name":"Leeds Cancer Centre, University of Leeds, Leeds, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0693-4202","authenticated-orcid":false,"given":"Noa","family":"Biran","sequence":"additional","affiliation":[{"name":"John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6487-276X","authenticated-orcid":false,"given":"Kwee","family":"Yong","sequence":"additional","affiliation":[{"name":"Department of Haematology, University College London Hospitals National Health Service (NHS) Foundation Trust, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4327-1957","authenticated-orcid":false,"given":"Vania","family":"Hungria","sequence":"additional","affiliation":[{"name":"Cl\u00ednica S\u00e3o Germano, S\u00e3o Paulo, Brazil;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Engelhardt","sequence":"additional","affiliation":[{"name":"Medical Department,"},{"name":"Hematology, Oncology and Stem Cell Transplantation, and"},{"name":"Clinical Cancer Research Group, Faculty of Medicine, University of Freiburg, Freiburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Gay","sequence":"additional","affiliation":[{"name":"Myeloma Unit, Division of Hematology, University of Turin\/Azienda Ospedaliero-Universitaria Citt\u00e0 della Salute e della Scienza di Torino, Turin, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Garc\u00eda Feria","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital de Manises, Valencia, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3084-180X","authenticated-orcid":false,"given":"Stefania","family":"Oliva","sequence":"additional","affiliation":[{"name":"Hematology Laboratory, University of Turin, Turin, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3650-4588","authenticated-orcid":false,"given":"Rimke","family":"Oostvogels","sequence":"additional","affiliation":[{"name":"Department of Haematology, University Medical Centre, Utrecht, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Gozzetti","sequence":"additional","affiliation":[{"name":"Department of Hematology, University of Siena, Siena, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara","family":"Rosenbaum","sequence":"additional","affiliation":[{"name":"Center for Myeloma, New York Presbyterian Hospital-Weill Cornell Medical Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward A.","family":"Stadtmauer","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University Hospital of W\u00fcrzburg, W\u00fcrzburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1797-8657","authenticated-orcid":false,"given":"Meral","family":"Beksac","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ankara University, Ankara, Turkey;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Weisel","sequence":"additional","affiliation":[{"name":"II Medizinische Klinik, Universit\u00e4tsklinikum Hamburg-Eppendorf, Hamburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA;"},{"name":"Department of Medical Oncology, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda-Victoria","family":"Mateos","sequence":"additional","affiliation":[{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca (IBSAL), University Hospital of Salamanca, Salamanca, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Hospital H\u00f4tel-Dieu, Nantes, France;"},{"name":"Intergroupe Francophone du My\u00e9lome (IFM), Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9183-4857","authenticated-orcid":false,"given":"Jesus","family":"San-Miguel","sequence":"additional","affiliation":[{"name":"Cl\u00ednica Universidad de Navarra and"},{"name":"Centro de Investigacion Medica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain;"},{"name":"Instituto de Investigacion Sanitaria de Navarra (IDISNA), Pamplona, Spain;"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBER-ONC), Pamplona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil C.","family":"Munshi","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA;"},{"name":"Department of Medical Oncology, Harvard Medical School, Boston, MA;"},{"name":"US Department of Veterans Affairs (VA) Boston Healthcare System, Boston, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Avet-Loiseau","sequence":"additional","affiliation":[{"name":"Intergroupe Francophone du My\u00e9lome (IFM), Paris, France;"},{"name":"Centre de Recherche en Canc\u00e9rologie de Toulouse, Unit\u00e9 1037, INSERM, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"4","key":"2020122416310066200_B1","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/s41564-020-0695-z","article-title":"The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2","volume":"5","author":"Coronaviridae Study Group of the International Committee on Taxonomy of Viruses","year":"2020","journal-title":"Nat Microbiol"},{"issue":"10241","key":"2020122416310066200_B2","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(20)31187-9","article-title":"Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study","volume":"395","author":"Kuderer","year":"2020","journal-title":"Lancet"},{"issue":"10241","key":"2020122416310066200_B3","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/S0140-6736(20)31173-9","article-title":"COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study","volume":"395","author":"Lee","year":"2020","journal-title":"Lancet"},{"issue":"9","key":"2020122416310066200_B4","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1001\/jamaoncol.2020.2586","article-title":"Risk of COVID-19 in patients with cancer","volume":"6","author":"Robinson","year":"2020","journal-title":"JAMA Oncol"},{"issue":"8","key":"2020122416310066200_B5","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/s41591-020-0979-0","article-title":"Determinants of COVID-19 disease severity in patients with cancer","volume":"26","author":"Robilotti","year":"2020","journal-title":"Nat Med"},{"issue":"7","key":"2020122416310066200_B6","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S1470-2045(20)30309-0","article-title":"Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study","volume":"21","author":"Tian","year":"2020","journal-title":"Lancet Oncol"},{"issue":"18","key":"2020122416310066200_B7","first-page":"1775","article-title":"Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy","volume":"323","author":"Onder","year":"2020","journal-title":"JAMA"},{"issue":"7","key":"2020122416310066200_B8","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1182\/blood-2018-11-877795","article-title":"Introduction to a review series on advances in multiple myeloma [editorial]","volume":"133","author":"Avet-Loiseau","year":"2019","journal-title":"Blood"},{"issue":"5","key":"2020122416310066200_B9","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1365-2141.2007.06705.x","article-title":"Immunodeficiency and immunotherapy in multiple myeloma","volume":"138","author":"Pratt","year":"2007","journal-title":"Br J Haematol"},{"issue":"1","key":"2020122416310066200_B10","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3324\/haematol.2014.107714","article-title":"Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients","volume":"100","author":"Blimark","year":"2015","journal-title":"Haematologica"},{"issue":"1","key":"2020122416310066200_B11","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/PPO.0000000000000355","article-title":"Novel agents in multiple myeloma","volume":"25","author":"Szalat","year":"2019","journal-title":"Cancer J"},{"issue":"3","key":"2020122416310066200_B12","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/nrclinonc.2012.15","article-title":"Latest advances and current challenges in the treatment of multiple myeloma","volume":"9","author":"Mahindra","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"2020122416310066200_B13","doi-asserted-by":"crossref","first-page":"e480","DOI":"10.3324\/haematol.2019.236588","article-title":"Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk","volume":"105","author":"Corre","year":"2020","journal-title":"Haematologica"},{"issue":"7","key":"2020122416310066200_B14","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.transproceed.2020.02.068","article-title":"Infectious complications in patients with multiple myeloma after high-dose chemotherapy followed by autologous stem cell transplant: nationwide study of the Infectious Complications Study Group of the Polish Adult Leukemia Group","volume":"52","author":"Waszczuk-Gajda","year":"2020","journal-title":"Transplant Proc"},{"issue":"8","key":"2020122416310066200_B15","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1038\/s41375-020-0876-z","article-title":"Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)","volume":"34","author":"Terpos","year":"2020","journal-title":"Leukemia"},{"issue":"8","key":"2020122416310066200_B16","doi-asserted-by":"crossref","first-page":"e1003","DOI":"10.1016\/S2214-109X(20)30264-3","article-title":"Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study","volume":"8","author":"Clark","year":"2020","journal-title":"Lancet Glob Health"},{"issue":"8","key":"2020122416310066200_B17","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1038\/s41375-020-0911-0","article-title":"Risk factors for death in 1859 subjects with COVID-19","volume":"34","author":"Chen","year":"2020","journal-title":"Leukemia"},{"issue":"7","key":"2020122416310066200_B18","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/s41577-020-0351-0","article-title":"Risk factors for death from COVID-19 [published correction appears in Nat Rev Immunol. 2020;20(7):448]","volume":"20","author":"Esai Selvan","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"2020122416310066200_B19","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1158\/2643-3230.BCD-20-0102","article-title":"COVID-19 infections and clinical outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers [published correction appears in Blood Cancer Discov. 1(3):290]","volume":"1","author":"Hultcrantz","year":"2020","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"2020122416310066200_B20","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13045-020-00934-x","article-title":"A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward","volume":"13","author":"Wang","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"10","key":"2020122416310066200_B21","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41408-020-00372-5","article-title":"Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality","volume":"10","author":"Mart\u00ednez-L\u00f3pez","year":"2020","journal-title":"Blood Cancer J"},{"issue":"6500","key":"2020122416310066200_B22","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1126\/science.abc3517","article-title":"Estimating the burden of SARS-CoV-2 in France","volume":"369","author":"Salje","year":"2020","journal-title":"Science"},{"key":"2020122416310066200_B23","article-title":"Dexamethasone in hospitalized patients with Covid-19: preliminary report [published online ahead of print 17 July 2020]","author":"RECOVERY Collaborative Group","journal-title":"N Engl J Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/136\/26\/3033\/1795491\/bloodbld2020008150.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/136\/26\/3033\/1795491\/bloodbld2020008150.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,24]],"date-time":"2020-12-24T11:52:57Z","timestamp":1608810777000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/136\/26\/3033\/474113\/Clinical-features-associated-with-COVID-19-outcome"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,24]]},"references-count":23,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2020,12,24]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2020008150","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.08.24.20177576","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,24]]}}}